Intellia Therapeutics Inc. (NTLA)

14.41
0.46 3.09
NASDAQ : Health Technology
Prev Close 14.87
Open 14.91
Day Low/High 14.39 / 15.04
52 Wk Low/High 11.03 / 32.95
Volume 272.57K
Avg Volume 570.50K
Exchange NASDAQ
Shares Outstanding 48.88M
Market Cap 724.82M
EPS -2.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

These Intriguing ETFs Are on the Cutting Edge of Disruptive Technologies

These Intriguing ETFs Are on the Cutting Edge of Disruptive Technologies

Ark Invest has developed a series of specialized exchange-traded funds that own shares in companies involved in 'disruptive innovation.'

First Week Of February 15th Options Trading For Intellia Therapeutics (NTLA)

First Week Of February 15th Options Trading For Intellia Therapeutics (NTLA)

Investors in Intellia Therapeutics Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NTLA options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

RSI Alert: Intellia Therapeutics (NTLA) Now Oversold

RSI Alert: Intellia Therapeutics (NTLA) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Intellia Therapeutics Is Now Oversold (NTLA)

Intellia Therapeutics Is Now Oversold (NTLA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Interesting NTLA Put And Call Options For November 16th

Interesting NTLA Put And Call Options For November 16th

Investors in Intellia Therapeutics Inc saw new options become available this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NTLA options chain for the new November 16th contracts and identified one put and one call contract of particular interest.

First Week Of NTLA September 21st Options Trading

First Week Of NTLA September 21st Options Trading

Investors in Intellia Therapeutics Inc saw new options begin trading this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NTLA options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

First Week Of NTLA August 17th Options Trading

First Week Of NTLA August 17th Options Trading

Investors in Intellia Therapeutics Inc saw new options become available this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NTLA options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

Intellia Therapeutics Has Upside in Its DNA

Intellia Therapeutics Has Upside in Its DNA

The setup here is appealing enough to take a small, aggressive shot on the long side.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMED, BCOV, CLS, DWSN, EDR, EQC, IFF, ONDK, PAGP, PKE, PTR, SJI, SRE, SWM, TRMB, TWIN Downgrades: ANDE, CBT, COLL, FLEX, GPK, GSM, HI, NAP, NTLA, RGS, UONE, UONEK Initiations: ELVT, SNDR Read on to get TheStreet Quant Ratings' detailed report:

First Week Of NTLA June 15th Options Trading

Investors in Intellia Therapeutics Inc saw new options begin trading this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NTLA options chain for the new June 15th contracts and identified one put and one call contract of particular interest.

NTLA Crosses Above Key Moving Average Level

In trading on Wednesday, shares of Intellia Therapeutics Inc crossed above their 200 day moving average of $21.75, changing hands as high as $22.12 per share. Intellia Therapeutics Inc shares are currently trading up about 5.3% on the day.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BID, CQP, FFWM, LNTH, NTLA, NXRT, SUM, TRGP, WR Downgrades: ALOT, EQM, GDS, GIGM, NBLX, ORCL, RAIL, VOC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Interesting NTLA Put And Call Options For February 2018

Interesting NTLA Put And Call Options For February 2018

Investors in Intellia Therapeutics Inc saw new options become available this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NTLA options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ENTL, SCHL, WILC Downgrades: BLL, DLTH, INTL, MDSO, NTLA, PNR Initiations: PVAC Read on to get TheStreet Quant Ratings' detailed report:

Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers

Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers

Oncology firm released results that show increased compliance with Optune predicted increased survival in patients with glioblastoma, a form of brain cancer.

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.

Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers

Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers

The Cambridge, Mass.-based company and Mylan said that M834, a proposed biosimilar of Orencia (abatacept), did not achieve its primary pharmacokinetic endpoints in a Phase 1 study.

TheStreet Quant Rating: D+ (Sell)